This Month's Clinical Focus: Hematology
A new clot-busting drug may take the place of
treatment-standard Plavix by year end
Focus is
on patients with acute coronary syndrome, which includes angina and
heart attack.
In a new trial, the upstart drug, ticagrelor (Brilinta) reduced the risk of second heart attacks and death without raising the risk of bleeding, as clopidogrel (Plavix) can do. The study was funded by AstraZeneca, which makes Brilinta.
"For people with acute coronary syndrome, this very well may replace Plavix," said study author Dr. Christopher Cannon, a cardiologist with Brigham and Women's Hospital and an associate professor of medicine at Harvard Medical School, both in Boston. "This is pretty compelling evidence from this trial that ticagrelor is better without any increased risk of bleeding."
The study was published in the Jan. 14 online
edition of The
Lancet.
Approval for Brilinta from the U.S. Food and Drug Administration could come late this year, although it's difficult to predict the timing of such decisions, Cannon noted.
Earlier results from the trial were presented at several major medical conferences last year. These published results seem to be the final step in solidifying the ascendancy of the new drug over the mainstay, Plavix.
Combined with other blood-thinning therapies now in the pipeline, these findings may also mark the dawn of a new generation of blood thinners, experts say. Plavix is used with aspirin to prevent blood clots that can lead to heart attacks, stroke and death. It has been the standard of treatment for heart patients for about a decade, Cannon said.
But Plavix has its share of problems, namely a lag time between when it is administered and when it takes effect, and variability in how different individuals respond to it. And because of an increased risk of bleeding, Plavix must be discontinued before surgery, Cannon said.
In this study of more than 13,000 patients with acute coronary syndrome, Brilinta, which appears to be more potent than Plavix, emerged with several advantages over the old standby. Because it is processed as soon as it's swallowed (meaning it doesn't have to go through the liver), Brilinta kicks in faster than Plavix, Cannon explained.
"It's a more reliable level of anti-clotting effect. There's less variability," he stated. "At the dose we've chosen, it has about twice the level of anti-clotting effect, hence its benefit in preventing heart attacks and stent thrombosis [closure]."
And unlike Plavix, Brilinta is quickly
reversible: When you stop taking it, it stops working, whereas Plavix
binds to platelets for as long as they are around, Cannon noted. This
means patients could have surgery with a lower risk of bleeding.
The authors estimated that for every 1,000
patients using Brilinta instead of Plavix for one year, there would be 11
fewer deaths, 13 fewer heart attacks and six fewer cases of blocked
stents.
Drug maker Sanofi-Aventis, which markets Plavix in a partnership with Bristol-Myers Squibb, stood by the safety record of its product.
"Ticagrelor is an investigational drug, and has not been approved by any regulatory authorities," the company said in a statement released Wednesday. "Ticagrelor's efficacy and safety have been studied in a clinical trial setting in the ACS [acute coronary syndrome] population, and in the real-world setting the efficacy and safety is still unknown."
However, one expert was impressed by the latest findings on Brilinta. "These were top-line results," said Dr. Kirk Garratt, clinical director of interventional cardiovascular research at Lenox Hill Hospital in New York City. "It's important that, for the first time, we have a drug that is not only more powerful in its ability to control platelet behavior but able to do that without increasing bleeding. That's astonishing. "Still, enthusiasm may need to be tempered, he said.
Garratt did point out that the vast majority of participants in the trial came from Europe, the Middle East and Africa, not North America. "And in that group of North American patients, there was no benefit for ticagrelor," he said. "It could just be play of chance but you can't get around the fact that when the population was [studied] separately, there was no benefit."
Secondly, Brilinta needs to be taken twice a day to
maintain its effect, not once daily as with Plavix. "No matter how good you are about medicines, you're going to
miss some," Garratt. This, added to the fact
that the drug stops working if you stop taking it, means that a person who
forgets his or her medication at night could see their risk for heart
trouble rise by the morning.
"When it's morning again, you not only have made new platelets [which happens continuously] but the old platelets are springing back to life and people are most likely to form blood clots in the early morning hours," Garratt said. "I'm a little concerned about a drug that could leave a patient really unprotected in the early morning hours when they're most likely to form blood clots if they miss the evening dose, which will happen."
SOURCES: Christopher P. Cannon, M.D., cardiologist, Brigham and Women's Hospital, and associate professor, medicine, Harvard Medical School, Boston; Kirk Garratt, M.D., clinical director, interventional cardiovascular research, Lenox Hill Hospital, New York City; Jan. 13, 2010, news statement, Sanofi-Aventis U.S.; Jan. 14, 2010, The Lancet, online
If you want
to accelerate your clinical trials, you need to change the workflow
paradigm. Criterium knows resources are
precious, time is the enemy, and results are paramount. Our user-friendly technologies are integrated into all
aspects of our clinical development services for improved efficiencies.
And a talented in-house staff that is committed
to the professional support of our clients individual and particular needs
is the backbone of our processes for maximum client
outcomes.
Of particular interest to
you would be our experience with HEMATOLOGY TRIALS, including: Anemia -
Thermal injury, Anemia - Cancer treatments, Anti Coagulant for central
line, CABG, Factor VIII Antibodies, Hypercholesteremia,
Hyperlipidemia, Acute Myeloid Leukemia, Home Infusion Treatment,
Hemophilia & Hemophilia Factor VIII, Von Willebrand's Disease,
Thromboembolism in Gastric Cancer, and Sickle Cell Anemia. We have managed hematology trials for over 19
years.
We
have several propriety technology solutions available that are proven to
improve your clinical trial results.
Contact:
John Hudak, President at
jmhudak@criteriuminc.com
Of particular interest to you would be our experience with HEMATOLOGY TRIALS, including: Anemia - Thermal injury, Anemia - Cancer treatments, Anti Coagulant for central line, CABG, Factor VIII Antibodies, Hypercholesteremia, Hyperlipidemia, Acute Myeloid Leukemia, Home Infusion Treatment, Hemophilia & Hemophilia Factor VIII, Von Willebrand's Disease, Thromboembolism in Gastric Cancer, and Sickle Cell Anemia. We have managed hematology trials for over 19 years.
We
have several propriety technology solutions available that are proven to
improve your clinical trial results.
Contact:
CRITERIUM, Inc.
Global CRO Releases New Whitepaper
About Criterium Inc. Criterium Inc. www.criteriuminc.com is a global, full-service,
technology-driven contract research organization that offers a unique mix
of high-quality, innovative clinical research solutions for the
biopharmaceutical, pharmaceutical, medical device, and CRO
industries.
